The estimated Net Worth of Robert J More is at least $9.15 Миллион dollars as of 15 July 2021. Mr. More owns over 11,670 units of Vir Biotechnology Inc stock worth over $360,407 and over the last 19 years he sold VIR stock worth over $8,771,913. In addition, he makes $13,387 as Independent Director at Vir Biotechnology Inc.
Robert has made over 13 trades of the Vir Biotechnology Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 11,670 units of VIR stock worth $414,985 on 15 July 2021.
The largest trade he's ever made was buying 100,000 units of Vir Biotechnology Inc stock on 22 February 2019 worth over $250,000. On average, Robert trades about 10,573 units every 205 days since 2006. As of 15 July 2021 he still owns at least 46,029 units of Vir Biotechnology Inc stock.
You can see the complete history of Mr. More stock trades at the bottom of the page.
Robert J. More serves as Independent Director of the Company. Since October 2016, Mr. More has served as Managing Director of Alta Partners, a venture capital firm. From July 2013 to May 2015, Mr. More served as Senior Advisor for the Bill & Melinda Gates Foundation and led its Global Health Venture Initiative. He served as a General Partner of venture capital firms Frazier Healthcare Ventures and Domain Associates from September 2008 to June 2013 and from June 1996 to July 2008, respectively. Mr. More currently serves on the board of directors of Sienna Biopharmaceuticals, Inc., a public pharmaceutical company. He also currently serves on the board of directors of the following private companies: Affinivax, Inc., a biotechnology company, eGenesis, a biotechnology company, Qihan Biotech, a biotechnology company, Sirenas, LLC, a biotechnology company, Tyra Biosciences, Inc., a biotechnology company, and as an advisor on Liquiglide, Inc. a biotechnology company. Mr. More previously served on the board of directors of the following public companies: Achaogen, Inc., a biopharmaceutical company, Carticept Medical, Inc., a medical device company, Cartiva, a medical device company, Neothetics Inc., a pharmaceutical company, Glaukos Corporation, a medical technology company, and IntraLase Corp., a medical device company acquired by Advanced Medical Optics in 2007. He also previously served on the board of directors of the following life sciences companies: ESP Pharma, Inc., Proxima Therapeutics, Inc., NovaCardia, Inc., Esprit Pharma, Inc. and Oceana Therapeutics, Inc. Mr. More was a founding member of the board of directors of the Kauffman Fellows Program and previously served on the board of directors of One Revolution and The Foundation for Innovative New Diagnostics (FIND). Mr. More currently serves on one of the governing boards of the Biotechnology Innovation Organization (BIO). He received his B.S. in Biology from Middlebury College and an M.B.A. from the Darden School of Business Administration at the Universi
As the Independent Director of Vir Biotechnology Inc, the total compensation of Robert More at Vir Biotechnology Inc is $13,387. There are 16 executives at Vir Biotechnology Inc getting paid more, with George Scangos having the highest compensation of $3,944,610.
Robert's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I... и Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Vir Biotechnology Inc executives and other stock owners filed with the SEC include: